1. Home
  2. TBPH vs SLSR Comparison

TBPH vs SLSR Comparison

Compare TBPH & SLSR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • SLSR
  • Stock Information
  • Founded
  • TBPH 2013
  • SLSR 2018
  • Country
  • TBPH United States
  • SLSR Switzerland
  • Employees
  • TBPH N/A
  • SLSR N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • SLSR
  • Sector
  • TBPH Health Care
  • SLSR
  • Exchange
  • TBPH Nasdaq
  • SLSR NYSE
  • Market Cap
  • TBPH 464.5M
  • SLSR 539.0M
  • IPO Year
  • TBPH N/A
  • SLSR N/A
  • Fundamental
  • Price
  • TBPH $10.77
  • SLSR $4.61
  • Analyst Decision
  • TBPH Buy
  • SLSR Buy
  • Analyst Count
  • TBPH 3
  • SLSR 2
  • Target Price
  • TBPH $11.33
  • SLSR $11.00
  • AVG Volume (30 Days)
  • TBPH 379.4K
  • SLSR 35.5K
  • Earning Date
  • TBPH 05-08-2025
  • SLSR 05-15-2025
  • Dividend Yield
  • TBPH N/A
  • SLSR N/A
  • EPS Growth
  • TBPH N/A
  • SLSR N/A
  • EPS
  • TBPH N/A
  • SLSR N/A
  • Revenue
  • TBPH $65,266,000.00
  • SLSR N/A
  • Revenue This Year
  • TBPH $51.09
  • SLSR N/A
  • Revenue Next Year
  • TBPH N/A
  • SLSR N/A
  • P/E Ratio
  • TBPH N/A
  • SLSR N/A
  • Revenue Growth
  • TBPH 6.11
  • SLSR N/A
  • 52 Week Low
  • TBPH $7.44
  • SLSR $1.90
  • 52 Week High
  • TBPH $11.82
  • SLSR $4.68
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 64.32
  • SLSR 63.49
  • Support Level
  • TBPH $9.10
  • SLSR $4.25
  • Resistance Level
  • TBPH $11.82
  • SLSR $4.54
  • Average True Range (ATR)
  • TBPH 0.39
  • SLSR 0.22
  • MACD
  • TBPH 0.19
  • SLSR 0.02
  • Stochastic Oscillator
  • TBPH 62.23
  • SLSR 85.74

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About SLSR SOLARIS RESOURCES INC

Solaris Resources Inc is advancing a portfolio of copper and gold assets in the Americas, which includes a high-grade resource with expansion and additional discovery potential at the Warintza copper and gold project in Ecuador; discovery potential on the grass-roots Tamarugo project in Chile and Capricho and Paco Orco projects in Peru, and the La Verde joint venture project.

Share on Social Networks: